Alnylam’s Amvuttra Market May See Tenfold Increase After Phase III Win

The company posted positive results from the HELIOS-B trial in patients with ATTR-CM, which represents a much larger population than the approved hATTR-PN indication.

• Source: Shutterstock

Alnylam Pharmaceuticals Inc. stands to significantly increase the addressable population for Amvuttra (vutrisiran) with positive Phase III data in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM). However, without detailed data from the clinical trial, the commercial prospects remain unclear given the lengthened follow-up in the study and the increasingly competitive market.

The Cambridge, MA-based biotech announced topline results from the HELIOS-B study in ATTR-CM on 24 June, stating that the study met its primary endpoint, a composite of all-cause mortality and recurrent cardiovascular events during the double-blind period in the overall population – including those who received

Key Takeaways
  • Alnylam plans to file a supplemental approval application with the FDA to expand the label for Amvuttra after positive results from the HELIOS-B trial in ATTR-CM.

  • The company projects a tenfold increase in the addressable patient population for the drug, which brought in $195m in revenue in the first quarter

More from Clinical Trials

More from R&D